secwatch / observer
VCYT VERACYTE, INC.
CIK 0001384101 45 ready 8-Ks latest July 30, 2026, 4:18 PM ET RSS · JSON
Activity: QUIET 0 filings / 30d vs 1 baseline
Ready 8-Ks 45
Latest filing July 30, 2026, 4:18 PM ET
Top materiality 0.90
Event mix earnings ×22 · leadership ×9 · other_material ×5
Sentiment 22 pos · 0 neg · 23 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for VCYT

Highest-materiality recent filing

Veracyte acquires C2i Genomics for $70M in stock; reports preliminary 2023 revenue up 21%

January 8, 2024, 6:59 PM ET M&A materiality 0.90 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases ×3

Read filing →

Executive changes

Appointed

Tom Miller

Director
VCYT · VERACYTE, INC.
Effective
2024-09-03
Filed
September 4, 2024, 7:59 PM ET
the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.
Appointed

Brent Shafer

Director
VCYT · VERACYTE, INC.
Effective
2024-09-03
Filed
September 4, 2024, 7:59 PM ET
the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.
Departed

John L. Bishop

Director
VCYT · VERACYTE, INC.
Filed
February 13, 2024, 6:59 PM ET
On February 7, 2024, John L. Bishop, a member of the Board of Directors (the “Board”) of Veracyte, Inc. (the “Company”), informed the Chair of the Board that he will retire at the end of his current term as director and not stand for reelection at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”).
Departed

Tina S. Nova

General Manager, Urological Cancers
VCYT · VERACYTE, INC.
Effective
2023-09-03
Filed
August 8, 2023, 7:59 PM ET
On August 4, 2023, the Company and Tina S. Nova, Ph.D. agreed that Dr. Nova will resign from her position as General Manager, Urological Cancers of the Company effective as of September 3, 2023
Departed

Giulia C. Kennedy

Global Chief Scientific Officer and Chief Medical Officer
VCYT · VERACYTE, INC.
Effective
2022-12-31
Filed
December 14, 2022, 6:59 PM ET
On December 9, 2022, Giulia C. Kennedy, Ph.D, Global Chief Scientific Officer and Chief Medical Officer of Veractye, Inc. (the “Company”), and the Company agreed that she would depart from the Company, effective December 31, 2022.
Appointed

Eliav Barr, M.D.

Director
VCYT · VERACYTE, INC.
Effective
2022-08-09
Filed
August 11, 2022, 7:59 PM ET
the Board appointed Eliav Barr, M.D., to serve as a director of the Company, effective immediately.
Appointed

Jonathan Wygant

Vice President and Chief Accounting Officer
VCYT · VERACYTE, INC.
Effective
2022-03-01
Filed
February 22, 2022, 6:59 PM ET
On February 22, 2022, Veracyte, Inc. (the “Company”) announced the appointment of Jonathan Wygant, 51, as its Vice President and Chief Accounting Officer.
Role change

Beverly Jane Alley

Vice President, Accounting
VCYT · VERACYTE, INC.
Effective
2022-02-22
Filed
February 22, 2022, 6:59 PM ET
In addition, effective February 22, 2022, Beverly Jane Alley, the Company’s Vice President and Chief Accounting Officer, was appointed the Company’s Vice President, Accounting.
Departed

Beverly Jane Alley

Vice President, Accounting
VCYT · VERACYTE, INC.
Effective
2022-06-30
Filed
February 22, 2022, 6:59 PM ET
Ms. Alley’s service as Vice President, Accounting would continue through June 30, 2022, at which time, in exchange for a standard release of claims, she would depart from the Company and receive three months’ salary and continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
Appointed

Tina S. Nova, Ph.D.

President of the Company’s CLIA U.S. business
VCYT · VERACYTE, INC.
Effective
2022-01-06
Filed
January 11, 2022, 6:59 PM ET
On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.
Departed

James H. Erlinger III

Executive Vice President, General Counsel and Secretary
VCYT · VERACYTE, INC.
Effective
2021-07-31
Filed
July 16, 2021, 7:59 PM ET
On July 13, 2021, James H. Erlinger III, Executive Vice President, General Counsel and Secretary of Veracyte, Inc. (the “Company”), announced his retirement from the Company, effective as of July 31, 2021.
Departed

Jane Alley

Acting Chief Financial Officer
VCYT · VERACYTE, INC.
Effective
2021-07-19
Successor
Rebecca Chambers
Filed
July 12, 2021, 7:59 PM ET
Jane Alley, Acting Chief Financial Officer, would be resigning from her position as Acting Chief Financial Officer, effective as of July 19, 2021

Earnings & guidance

2026-Q1 EPS reported $0.35 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

22 positive 0 negative 23 neutral

source · VCYT on sec.gov